BR112022019076A2 - Composição e método - Google Patents

Composição e método

Info

Publication number
BR112022019076A2
BR112022019076A2 BR112022019076A BR112022019076A BR112022019076A2 BR 112022019076 A2 BR112022019076 A2 BR 112022019076A2 BR 112022019076 A BR112022019076 A BR 112022019076A BR 112022019076 A BR112022019076 A BR 112022019076A BR 112022019076 A2 BR112022019076 A2 BR 112022019076A2
Authority
BR
Brazil
Prior art keywords
composition
disorder
purifying
cancer
treating
Prior art date
Application number
BR112022019076A
Other languages
English (en)
Portuguese (pt)
Inventor
Dunn Rosanne
Alahari Arunakumari
Original Assignee
HaemaLogiX Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020900948A external-priority patent/AU2020900948A0/en
Application filed by HaemaLogiX Ltd filed Critical HaemaLogiX Ltd
Publication of BR112022019076A2 publication Critical patent/BR112022019076A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/20—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the sorbent material
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Water Supply & Treatment (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
BR112022019076A 2020-03-27 2021-03-26 Composição e método BR112022019076A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2020900948A AU2020900948A0 (en) 2020-03-27 Composition and method
US202163200752P 2021-03-25 2021-03-25
PCT/IB2021/000171 WO2021191684A1 (en) 2020-03-27 2021-03-26 Composition and method

Publications (1)

Publication Number Publication Date
BR112022019076A2 true BR112022019076A2 (pt) 2023-01-10

Family

ID=77890984

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022019076A BR112022019076A2 (pt) 2020-03-27 2021-03-26 Composição e método

Country Status (9)

Country Link
US (3) US20240262928A1 (enExample)
EP (1) EP4126900A4 (enExample)
JP (1) JP7817945B2 (enExample)
KR (1) KR20230004543A (enExample)
CN (1) CN115551877A (enExample)
AU (1) AU2021244846A1 (enExample)
BR (1) BR112022019076A2 (enExample)
CA (1) CA3176109A1 (enExample)
WO (1) WO2021191684A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025213238A1 (en) * 2024-04-12 2025-10-16 HaemaLogiX Ltd Anti-kma antibody formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002344701B2 (en) * 2001-07-06 2006-03-30 Haemalogix Pty Ltd Method for treating multiple myeloma
AUPR617901A0 (en) 2001-07-06 2001-08-02 Pacmab Pty Ltd Method for treating multiple myeloma
SG10201401310VA (en) * 2009-04-07 2014-06-27 Immune System Therapeutics Ltd Method for treating immune disorders
DK3272764T3 (da) * 2009-12-18 2024-05-06 Novartis Ag Fremgangsmåde til affinitetskromatografi
WO2016031932A1 (ja) * 2014-08-27 2016-03-03 田辺三菱製薬株式会社 アルカリ洗浄によるＦｃ領域を有するタンパク質の製造方法
EP3268100A1 (en) * 2015-03-13 2018-01-17 Bristol-Myers Squibb Company Use of alkaline washes during chromatography to remove impurities
RU2743188C2 (ru) * 2015-04-23 2021-02-16 Хемалоджикс Пти. Лтд. Химерные антигенные рецепторы к каппа-антигену миеломы и варианты их применения
EP3492493A4 (en) 2016-07-28 2020-03-18 Kaneka Corporation METHOD FOR PRODUCING AN ANTIBODY FRAGMENT
WO2019191416A1 (en) * 2018-03-29 2019-10-03 Bristol-Myers Squibb Company Methods of purifying monomeric monoclonal antibodies

Also Published As

Publication number Publication date
EP4126900A1 (en) 2023-02-08
KR20230004543A (ko) 2023-01-06
US20240262928A1 (en) 2024-08-08
JP2023518905A (ja) 2023-05-08
US20240262925A1 (en) 2024-08-08
WO2021191684A1 (en) 2021-09-30
EP4126900A4 (en) 2024-05-29
JP7817945B2 (ja) 2026-02-19
CA3176109A1 (en) 2021-09-30
CN115551877A (zh) 2022-12-30
AU2021244846A1 (en) 2022-11-24
US20260035474A1 (en) 2026-02-05

Similar Documents

Publication Publication Date Title
SA520420458B1 (ar) نظائر رابامايسين مرتبطة بـ C40، C28، وC32 mTOR كمثبطات
PH12021553000A1 (en) Multispecific proteins
SA521422303B1 (ar) مثبطات عضو عائلة الكنيسين 18 أ
BR112022021884A2 (pt) Proteínas que se ligam a nkg2d, cd16 e clec12a
PH12022550399A1 (en) MTA-Cooperative PRMT5 Inhibitors
BR112021006229A2 (pt) composto, composição farmacêutica, e, método para tratamento de um câncer
MX2025003445A (es) Amidas heterobiciclicas como inhibidoras del cumulo de diferenciacion 38 (cd38)
BR112022002442A2 (pt) Terapias de imuno-oncologia com conjugados de il-2
MX2019010040A (es) Composiciones y métodos para el tratamiento del cáncer.
MX2024002391A (es) Inhibidores de indolina de kif18a.
MX2024013215A (es) Compuestos para inhibir kif18a
BR112022007128A2 (pt) Ligação de proteínas nkg2d, cd16 e flt3
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
BR112023023578A2 (pt) Composto, composição farmacêutica compreendendo o composto e método de tratamento de uma leucemia aguda
BR112022014435A2 (pt) Composição herbicida líquida e métodos para aumentar a atividade herbicida de composições herbicidas líquidas e para tratar o material de propagação de plantas
MX2022000310A (es) Inhibidores de proteina bcl-2.
BR112022012473A2 (pt) Composição de tratamento capilar, e, métodos para tratar cabelo, para melhorar a condição do cabelo e para diminuir o ph do cabelo
MX2018011162A (es) Metodos de purificacion de colageno 7.
WO2024006292A3 (en) Methods of treating cancer
EP4674415A3 (en) Azaquinolines as inhibitors of cd38
EA202192288A1 (ru) Соединения на основе нейрегулина-4 и способы их применения
MX2021011524A (es) Inhibidores de proteina arginina n-metiltransferasa 5 (prmt5) y usos de los mismos.
BR112022000229A2 (pt) Composição para uso no tratamento da perda de cabelo
WO2024163641A3 (en) Formulations for treating cancer
WO2021100029A3 (en) Prodrugs of fulvestrant